| Índia | Turki | Austria | |
| Imunoterapi dengan Keytruda (Pembrolizumab) | dari $3,500 | dari $3,300 | dari $15,000 |
Bookimed tidak menambah biaya tambahan dalam harga Imunoterapi dengan Keytruda (Pembrolizumab). Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik untuk Imunoterapi dengan Keytruda (Pembrolizumab) Anda saat tiba.
Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam Imunoterapi dengan Keytruda (Pembrolizumab) dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.
Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan Imunoterapi dengan Keytruda (Pembrolizumab) Anda.
Dr. Ahmer Arif Shaikh berspesialisasi dalam pengobatan kanker mulut dan rehabilitasi fungsional di HCG Manavata Cancer Centre.
Dr. Chaitainya Borde telah melakukan lebih dari 30.000 pemindaian PET dan merawat 1.000+ pasien kanker tiroid di HCG Manavata Cancer Centre.
Lebih dari 19 tahun pengalaman onkologi bedah – Dr. Nagarkar telah melakukan lebih dari 50.000 operasi kanker di HCG Manavata Cancer Centre.
Dr. Girish Badarkhe berspesialisasi dalam mengobati kanker darah dengan imunoterapi di HCG Manavata Cancer Centre, menawarkan lebih dari 13 tahun keahlian terfokus.
Keytruda is an immunotherapy medication that reboots the immune system to identify and kill cancer cells. Unlike chemotherapy, this monoclonal antibody blocks the PD-1 pathway, preventing tumors from hiding and allowing T cells to naturally destroy advanced cancers like melanoma or lung carcinoma.
Bookimed Expert Insight: India has become a global hub for Keytruda due to high-volume expertise at centers like HCG Manavata Cancer Centre, where teams have performed over 50,000 surgeries. While US infusions average $21,500, Indian clinics offer the same immunotherapy starting at $3,500, saving patients up to 77%.
Patient Consensus: Patients emphasize that immunotherapy feels different from chemotherapy because it revs up immunity rather than poisoning cells. many report that monitoring biomarkers like PD-L1 was crucial for predicting their individual success with the drug.
Keytruda is approved in India by the Drug Controller General of India (DCGI). It is cleared for multiple cancer indications including non-small cell lung cancer, melanoma, and triple-negative breast cancer. Treatment is available at JCI-accredited facilities like Artemis Hospitals and Apollo Hospital Indraprastha.
Bookimed Expert Insight: Success with Keytruda in India often depends on doctor experience with immunotherapy protocols. Dr. Shruti Kate at HCG Manavata Cancer Centre specializes specifically in these treatments. Many top Indian clinics now also use IBM Watson AI platforms to verify treatment compatibility.
Patient Consensus: Success depends on confirming drug availability for your specific cancer subtype before traveling. Patients highly value the cost difference but recommend asking about immune-related side effect monitoring plans.